Predictive Oncology Platform and Utility Protocols (Q11677): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in 1 language: translated_label)
(‎Removed claim: summary (P836): It is a project of high technological level and a high level of innovation which aims to significantly increase the product potential of the Institute of Applied Biotechnologies a.s. (IAB) in cooperation with the research partner of the Faculty of Medicine of Palacký University in Olomouc, namely the Institute of Molecular and Translation Medicine (UMTM). The objective is the development of products for predictive cancer diagnostics, based on...)
Property / summary
It is a project of high technological level and a high level of innovation which aims to significantly increase the product potential of the Institute of Applied Biotechnologies a.s. (IAB) in cooperation with the research partner of the Faculty of Medicine of Palacký University in Olomouc, namely the Institute of Molecular and Translation Medicine (UMTM). The objective is the development of products for predictive cancer diagnostics, based on circulating cell cells/DNA/RNA. a. (English)
 
Property / summary: It is a project of high technological level and a high level of innovation which aims to significantly increase the product potential of the Institute of Applied Biotechnologies a.s. (IAB) in cooperation with the research partner of the Faculty of Medicine of Palacký University in Olomouc, namely the Institute of Molecular and Translation Medicine (UMTM). The objective is the development of products for predictive cancer diagnostics, based on circulating cell cells/DNA/RNA. a. (English) / rank
Normal rank
 

Revision as of 15:32, 22 October 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Predictive Oncology Platform and Utility Protocols
Project in Czech Republic financed by DG Regio

    Statements

    contained in NUTS
    Prague
    0 references
    country
    Czechia
    0 references
    EU contribution
    39,804,511.31 Czech koruna
    0 references
    1,592,180.45 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    budget
    61,769,881.0 Czech koruna
    0 references
    2,470,795.24 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    co-financing rate
    64.44 percent
    0 references
    expected end time
    31 October 2020
    0 references
    beneficiary name (string)
    Institute of Applied Biotechnologies a.s.
    0 references
    coordinate location

    50°5'1.93"N, 14°30'28.48"E
    0 references
    postal code
    10800
    0 references
    10800
    0 references
    summary
    Jedná se o projekt vysoké technologické úrovně a vysoké míry inovace, který si klade za cíl významně zvýšit produktový potenciál společnosti Institute of Applied Biotechnologies a.s. (IAB) ve spolupráci s výzkumným partnerem Lékařskou fakultou Univerzity Palackého v Olomouci, jmenovitě Ústavem molekulární a translační medicíny (UMTM). Cílem je vývoj produktů pro prediktivní onkologickou diagnostiku založenou na cirkulujících buňkách / DNA / RNA. a. (Czech)
    0 references

    Identifiers

    Czech Kohesio ID
    CZ.01.1.02/0.0/0.0/17_107/0012422
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q11677&oldid=6599387"